@dansfera: That Complete Response Letter (CRL) on the biotech front wasn't the death knell everyone feared—it’s being reframed as a 'half-approval.' 🧐 The underlying risk of *zero* approval? Surprisingly low, according to this analysis. We missed the immediate run to $8 or $9, which analysts thought would put it firmly in the $6–$12 bracket amid buyout chatter. The silver lining? The conviction remains that this destination *will* eventually be reached. Stay tuned. 📈 #BiotechStocks #StockMarket #Investing #FinanceTok #Pharma

dansfera

Open In TikTok:

Region: US

Thursday 05 February 2026 19:39:25 GMT